Medtronic plcMDT recently unveiled new three-year clinical outcomes from the high risk study of the CoreValve U.S. Pivotal Trial, at the 65th Annual Scientific Session & Expo of the American College ...

June 2, 2010 (Paris, France) — New registry data from operators using the CoreValve device for transcatheter aortic-valve implantations (TAVI) support the medium-term safety and efficacy of this fully ...

Please provide your email address to receive an email when new articles are posted on . Medtronic announced that the FDA has approved its self-expanding transcatheter CoreValve System for patients ...

In patients with severe aortic stenosis who are at prohibitive risk for surgery, transcatheter implantation of a self-expanding valve substantially reduces all-cause death and stroke at 1 year, ...

Mechanism and suitability The CoreValve is a bioprosthetic porcine pericardial valve mounted in a nitinol stent, which is compressed into an 18F delivery catheter. When deployed, it self-expands when ...

MINNEAPOLIS - Medtronic, Inc. today announced it has received Conformité Européenne (CE) Mark for valve-in-valve (VIV) procedures using the CoreValve® and CoreValve® Evolut(TM) transcatheter aortic ...

IRVINE, Calif.--(BUSINESS WIRE)--CoreValve (www.corevalve.com) announced today that it has signed a definitive agreement to be acquired by Medtronic, Inc. (NYSE: MDT). CoreValve’s transcatheter, ...

Minneapolis, MN - The long-awaited US trial of the CoreValve transcatheter aortic-valve system is set to begin soon now that the FDA has granted Medtronic an investigational device exemption (IDE) for ...

When Anthony Leto discovered he suffered from a severe heart valve condition, he knew he might not be able to receive care. The 92-year-old New Yorker has a history of heart trouble that labeled him ...

Medtronic CoreValve System The FDA has approved the CoreValve System, a self-expanding transcatheter for patients with severe aortic stenosis who are too ill or frail to have their aortic valves ...